Clinical Trial

Engineered Immune Effectors Against Ovarian Cancer

Name: Engineered Immune Effectors Against Ovarian Cancer — clinical trial record (NCT03362606)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.

Protocol Amendment History 7 amendments

This ClinicalTrials.gov record has been amended 7 times since 2017-11-29; most recent amendment 2026-06-18.

Trial Details

NCT Number	NCT03362606
Lead Sponsor	Shenzhen Geno-Immune Medical Institute
Conditions	Ovarian Cancer
Enrollment	20 participants
Start Date	2026-06-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-23